Clinical molecular imaging with PET agents other than 18F-FDG

Current Pharmaceutical Biotechnology

Volumn 11, Issue 6, 2010, Pages 545-554

  Hall, Lance T ^a   Struck, Aaron F ^a   Perlman, Scott B ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Molecular imaging; Molecular imaging agents; PET; PET CT; Positron emission tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; 5 HYDROXYTRYPTOPHAN; 6 FLUORODOPA F 18; AMMONIA N 13; CARBON 11; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; MALONONITRILE; METHIONINE C 11; NITROGEN 13; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; SODIUM FLUORIDE F 18; STRONTIUM 82; DIAGNOSTIC AGENT;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BONE SCINTISCANNING; BRAIN TUMOR; CARCINOID; CELL PROLIFERATION; COMPUTED TOMOGRAPHY SCANNER; DOSIMETRY; HEALTH CARE QUALITY; HUMAN; LARYNX CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOLECULAR IMAGING; MYOCARDIAL PERFUSION IMAGING; PANCREAS CANCER; PARKINSON DISEASE; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; RADIATION EXPOSURE; RECEIVER OPERATING CHARACTERISTIC; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME; IMAGE ENHANCEMENT; METHODOLOGY; REVIEW;

FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 79952115284     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110792246537     Document Type: Article

References (76)

1. Weber, D.A.; Greenberg, E.J.; Dimich, A.; Kenny, P.J.; Rothschild, E.O.; Myers, W.P.L.; Laughlin, J.S. Kinetics of radionuclides used for bone studies. J. Nucl. Med. 1969, 10(1), 8-17.
2. Schirrmeister, H.; Guhlmann, A.; Elsner, K.; Kotzerke, J.; Glatting, G.; Rentschler, M.; Neumaier, B.; Trager, H.; Nussle, K.; Reske, S.N. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18f pet. J. Nucl. Med. 1999, 40(10), 1623-1629.
3. Schirrmeister, H.; Glatting, G.; Hetzel, J.; Nussle, K.; Arslandemir, C.; Buck, A.K.; Dziuk, K.; Gabelmann, A.; Reske, S.N.; Hetzel, M. Prospective evaluation of the clinical value of planar bone scans, spect, and 18f-labeled naf pet in newly diagnosed lung cancer. J. Nucl. Med. 2001, 42(12), 1800-1804.
4. Even-Sapir, E.; Metser, U.; Flusser, G.; Zuriel, L.; Kollender, Y.; Lerman, H.; Lievshitz, G.; Ron, I.; Michani, E. Assessment of malignant skeletal disease: Initial experience with 18f-fluoride pet/ct and comparison between 18f-fluoride pet and 18f-fluoride pet/ct. J. Nucl. Med. 2004, 45(2), 272-278.
5. Mankoff, D.A.; Dehdashti, F.; Shields, A.F. Characterizing tumors using metabolic imaging: Pet imaging of cellular proliferation and steroid receptors. Neoplasia. 2000, 2. 71-88.
6. Shields, A.F.; Grierson, J.R.; Dohmen, B.M.; Machulla, H.J.; Stayanoff, J.C.; Lawhorn-Crews, J.M.; Obradovich, J.E.; Muzik, O.; Mangner, T.J. Imaging proliferation in vivo with [f-18]flt and positron emission tomography. Nat. Med. 1998, 4(11), 1334-1336.
7. Vesselle, H.; Grierson, J.R.; Peterson, L.M.; Muzi, M.; Mankoff, D.A.; Krohn, K.A. 18f-fluorothymidine radiation dosimetry in human pet imaging studies. J. Nucl. Med. 2003, 44(9), 1482-1488.
8. Chen, W.; Cloughesy, T.; Kamdar, N.; Satyamurthy, N.; Bergsneider, M.; Liau, L.; Mischel, P.; Czernin, J.; Phelps, M.; Silverman, D. Imaging proliferation in brain tumors with 18f-flt pet: Comparison with 18f-fdg. J. Nucl. Med. 2005, 46(6), 945-952.
9. van Waarde, A.; Cobben, D.; Suurmeijer, A.; Maas, B.; Vaalburg, W.; de Vries, E.; Jager, P.; Hoekstra, H.; Elsinga, P. Selectivity of 18f-flt and 18f-fdg for differentiating tumor from inflammation in a rodent model. J. Nucl. Med. 2004, 45(4), 695-700.
10. Yamamoto, Y.; Nishiyama, Y.; Kimura, N.; Ishikawa, S.; Okuda, M.; Bandoh, S.; Kanaji, N.; Asakura, M.; Ohkawa, M. Comparison of 18f-flt pet and 18f-fdg pet for preoperative staging in non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging. 2008, 35(236-245.
11. Herrmann, K.; Ott, K.; Buck, A.K.; Lordick, F.; Wilhelm, D.; Souvatzoglou, M.; Becker, K.; Schuster, T.; Wester, J.H.; Siewert, J.R.; Schwaiger, M.; Krause, B. Imaging gastric cancer with pet and the radiotracers 18f-flt and 18f-fdg: a comparative analysis. J. Nucl. Med. 2007, 48(12), 1945-1950.
12. Buck, A.K.; Halter, G.; Schirrmeister, H.; Kotzerke, J.; Wurziger, I.; Glatting, G.; Mattfeldt, T.; Neumaier, B.; Reske, S.N.; Hetzel, M. Imaging proliferation in lung tumors with pet: 18f-flt versus 18f-fdg. J. Nucl. Med. 2003, 44(9), 1426-1431.
13. Smyczek-Gargya, B.; Fersis, N.; Dittmann, H.; Vogel, U.; Reischl, G.; Machulla, H.-J.; Wallwiener, D.; Bares, R.; Dohmen, B. Pet with [f-18]fluorothymidine for imaging of primary breast cancer: A pilot study. Eur. J. Nucl. Med. Mol. Imaging. 2004, 31(720-724.
14. Wagner, M.; Seitz, U.; Buck, A.; Neumaier, B.; ASchultheib, S.; Bangerter, M.; Bommer, M.; Leithauser, F.; Wawra, E.; Munzert, G.; Reske, S. 3'-[f-18]fluoro-3'-deoxythymidine ([f-18]-flt) as positron emission tomography tracer for imaging proliferation in a murine b-cell lymphoma model and in the human disease. Cancer Res. 2003, 63(2681-2687.
15. Cobben, D.; van der Laan, B.; Maas, B.; Vaalburg, W.; Suurmeijer, A.; Hoekstra, H.; Jager, P., Elsinga, P. F-18-flt pet for visualization of laryngeal cancer: Comparison with f-18-fdg pet. J. Nucl. Med. 2004, 45(226-231.
16. Herrmann, K.; Erkan, M.; Eckel, F.; Krause, B.-J.; Wester, H.-J.; Kleeff, J.; Schmid, R.; Friess, H.; Buck, A. Evaluation of 3-deoxy-3-18fluorothymidine pet (flt-pet) for the detection of pancreatic cancer-comparison to fdg-pet/ct. J. Nucl. Med. 2009, 50(Suppl. 2), 1746.
17. Jager, P.; Chirakal, R.; Marriott, C.J.; Brouwers, A.H.; Koopmans, P., Gulenchyn, K.Y. 6-l-18f-fluorodihyddroxyphenylalanine pet in neuroendocrine tumors: Basic aspects and emerging clinical applications. J. Nucl. Med. 2008, 49(4), 573-586.
18. Becherer, A.; Szabo, M.; Karanikas, G.; Wunderbaldinger, P.; Angelberger, P.; Raderer, M.; Kurtaran, A.; Dudczak, R.; Kletter, K. Imaging of advanced neuroendocrine tumors with 18f-fdopa pet. J. Nucl. Med. 2004, 45(7), 1161-1167.
19. Ambrosini, V.; Tomassetti, P.; Rubello, D.; Campana, D.; Nanni, C.; Castellucci, P.; Farsad, M.; Montini, G.; Al-Nahhas, A.; Franchi, R.; Fanti, S. Role of f-18-dopa pet/ct imaging in the management of patients with in-111-pentetreotide negative gep tumours. Nucl. Med. Commun. 2007, 28, 473-477.
20. Otsuka, M.; Kuwabara, Y.; Ichiya, Y.; Hosokawa, S.; Sasaki, M.; Yoshida, T.; Fukumura, T.; Kato, M.; Masuda, K. Differentiating between multiple system atrophy and parkinson's disease by positron emission tomography with 18f-dopa and 18f-fdg. Ann. Nucl. Med. 1997, 11(3), 251-257.
21. Pacak, K.; Eisenhofer, G.; Goldstein, D.S. Functional imaging of endocrine tumors: Role of positron emission tomography. Endocr. Rev. 2004, 25. 568-580.
22. Koopmans, K.P.; Neels, O.C.; Kema, I.P.; Elsinga, P.; Sluiter, W.; Vanghillewe, K.; Brouwers, A.H.; Jager, P.; de Vries, E. Improved staging of patients with carcinoid and islet cell tumors with 18fdihydroxy-phenyl-alanine and 11c-5-hydroxy-tryptophan positron emission tomography. J. Clin. Oncol. 2008, 26(9), 1489-1495.
23. Reske, S.N.; N.M., B.; Neumaier, B.; Gottfried, H.W.; Finsterbusch, F.; Kocot, D.; Moller, P.; Glatting, G.; Perner, S. Imaging prostate cancer with 11c-choline pet/ct. J. Nucl. Med. 2006, 47(8), 1249-1254.
24. Scher, B.; Seitz, M.; Albinger, W.; Tiling, R.; Scherr, M.; Becker, H.; Souvatzoglou, M.; Gildehaus, F.; Wester, J.H.; Dresel, S. Value of 11c-choline pet and pet/ct in patients with suspected prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2007, 34(1), 45-53.
25. Beheshti, M.; Imamovic, L.; Broinger, G.; Vali, R.; Waldenberger, P.; Stoiber, F.; Nader, M.; Gruy, B.; Janetschek, G.; Langsteger, W. F-18 choline pet/ct in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: A prospective study of 130 patients. Radiology. 2010 254(3), 925-933.
26. Vees, H.; Buchegger, F.; Albrecht, S.; Khan, H.; Husarik, D.; Zaidi, H.; Soloviev, D.; Hany, T.F.; Miralbell, R. 18f-choline and/or 11c-acetate positron emission tomography: Detection of residual or progressive subclinical disease at very low prostatespecific antigen values (<1 ng/ml) after radical prostatectomy. J. Compilation. 2007, 99. 1415-1420.
27. Galldiks, N.; Ullrich, R.; Schroeter, M.; Fink, G.R.; Kracht, L.W. Volumetry of [(11)c]-methionine pet uptake and mri contrast enhancement in patients with recurrent glioblastoma multiforme. Eur. J. Nucl. Med. Mol. Imaging. 2010, 37(1), 84-92.
28. Herholz, K.; Herscovitch, P., Heiss, W.D. Neuropet: Positron emmission tomography in neuroscience and clinical neurology. ed.; Springer-Verlag Heidelberg Berlin: Berlin; New York, 2004.
29. Kracht, L.W.; Miletic, H.; Busch, S.; Jacobs, A.H.; Voges, J.; Hoevels, M.; Klein, J.C.; Herholz, K.; Heiss, W.D. Delineation of brain tumor extent with [11c]l-methionine positron emission tomography: Local comparison with stereotactic histopathology. Clin. Cancer Res. 2004, 10(21), 7163-7170.
30. Herholz, K.; Holzer, T.; Bauer, B.; Schroder, R.; Voges, J.; Ernestus, R.I.; Mendoza, G.; Weber-Luxenburger, G.; Lottgen, J.; Thiel, A.; Wienhard, K.; Heiss, W.D. 11c-methionine pet for differential diagnosis of low-grade gliomas. Neurology. 1998, 50(5), 1316-1322.
31. Jager, P.L.; Vaalburg, W.; Pruim, J.; de Vries, E.G.; Langen, K.J.; Piers, D.A. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J. Nucl. Med. 2001, 42(3), 432-445.
32. Kim, D.K.; Kanai, Y.; Choi, H.W.; Tangtrongsup, S.; Chairoungdua, A.; Babu, E.; Tachampa, K.; Anzai, N.; Iribe, Y.; Endou, H. Characterization of the system l amino acid transporter in t24 human bladder carcinoma cells. Biochim. Biophys. Acta. 2002, 1565(1), 112-121.
33. Bustany, P.; Chatel, M.; Derlon, J.M.; Darcel, F.; Sgouropoulos, P.; Soussaline, F.; Syrota, A. Brain tumor protein synthesis and histological grades: A study by positron emission tomography (pet) with c11-l-methionine. J. Neurooncol. 1986, 3(4), 397-404.
34. Pirotte, B.; Goldman, S.; Dewitte, O.; Massager, N.; Wikler, D.; Lefranc, F.; Ben Taib, N.O.; Rorive, S.; David, P.; Brotchi, J.; Levivier, M. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: A report of 103 consecutive procedures. J. Neurosurg. 2006, 104(2), 238-253.
35. Pirotte, B.J.; Levivier, M.; Goldman, S.; Massager, N.; Wikler, D.; Dewitte, O.; Bruneau, M.; Rorive, S.; David, P.; Brotchi, J. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: A survival analysis in 66 consecutive patients. Neurosurgery. 2009, 64(3), 471-481. discussion 481.
36. Terakawa, Y.; Tsuyuguchi, N.; Iwai, Y.; Yamanaka, K.; Higashiyama, S.; Takami, T.; Ohata, K. Diagnostic accuracy of 11c-methionine pet for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J. Nucl. Med. 2008, 49(5), 694-699.
37. Van Laere, K.; Ceyssens, S.; Van Calenbergh, F.; de Groot, T.; Menten, J.; Flamen, P.; Bormans, G.; Mortelmans, L. Direct comparison of 18f-fdg and 11c-methionine pet in suspected recurrence of glioma: Sensitivity, inter-observer variability and prognostic value. Eur. J. Nucl. Med. Mol. Imaging. 2005, 32(1), 39-51.
38. Alexiou, G.A.; Tsiouris, S.; Kyritsis, A.P.; Voulgaris, S.; Argyropoulou, M.I.; Fotopoulos, A.D. Glioma recurrence versus radiation necrosis: Accuracy of current imaging modalities. J. Neurooncol. 2009, 95(1), 1-11.
39. Klunk, W.E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D.P.; Bergstrom, M.; Savitcheva, I.; Huang, G.F.; Estrada, S.; Ausen, B.; Debnath, M.L.; Barletta, J.; Price, J.C.; Sandell, J.; Lopresti, B.J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C.A.; Langstrom, B. Imaging brain amyloid in alzheimer's disease with pittsburgh compound-b. Ann. Neurol. 2004, 55(3), 306-319.
40. Grimmer, T.; Henriksen, G.; Wester, H.J.; Forstl, H.; Klunk, W.E.; Mathis, C.A.; Kurz, A.; Drzezga, A. Clinical severity of alzheimer's disease is associated with pib uptake in pet. Neurobiol. Aging. 2009, 30(12), 1902-1909.
41. Mintun, M.A.; Larossa, G.N.; Sheline, Y.I.; Dence, C.S.; Lee, S.Y.; Mach, R.H.; Klunk, W.E.; Mathis, C.A.; DeKosky, S.T.; Morris, J.C. [11c]pib in a nondemented population: Potential antecedent marker of alzheimer disease. Neurology. 2006, 67(3), 446-452.
42. Rabinovici, G.D.; Furst, A.J.; O'Neil, J.P.; Racine, C.A.; Mormino, E.C.; Baker, S.L.; Chetty, S.; Patel, P.; Pagliaro, T.A.; Klunk, W.E.; Mathis, C.A.; Rosen, H.J.; Miller, B.L.; Jagust, W.J. 11c-pib pet imaging in alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007, 68(15), 1205-1212.
43. Resnick, S.M.; Sojkova, J.; Zhou, Y.; An, Y.; Ye, W.; Holt, D.P.; Dannals, R.F.; Mathis, C.A.; Klunk, W.E.; Ferrucci, L.; Kraut, M.A.; Wong, D.F. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11c]pib. Neurology. 2010, [Epub ahead of Print].
44. Mathis, C.A.; Wang, Y., Klunk, W.E. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr. Pharm. Des. 2004, 10(13), 1469-1492.
45. Klunk, W.E.; Lopresti, B.J.; Ikonomovic, M.D.; Lefterov, I.M.; Koldamova, R.P.; Abrahamson, E.E.; Debnath, M.L.; Holt, D.P.; Huang, G.F.; Shao, L.; DeKosky, S.T.; Price, J.C.; Mathis, C.A. Binding of the positron emission tomography tracer pittsburgh compound-b reflects the amount of amyloid-beta in alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25(46), 10598-10606.
46. Nordberg, A. Pet imaging of amyloid in alzheimer's disease. Lancet Neurol. 2004, 3(9), 519-527.
47. Rowe, C.C.; Ng, S.; Ackermann, U.; Gong, S.J.; Pike, K.; Savage, G.; Cowie, T.F.; Dickinson, K.L.; Maruff, P.; Darby, D.; Smith, C.; Woodward, M.; Merory, J.; Tochon-Danguy, H.; O'Keefe, G.; Klunk, W.E.; Mathis, C.A.; Price, J.C.; Masters, C.L.; Villemagne, V.L. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007, 68(20), 1718-1725.
48. Mathis, C.L., B.; Mason, N.; Price, J.; Flatt, N.; Bi, W.; Ziolko, S.; DeKosky, S.; Klunk, W. Comparison of the amyloid imaging agents [f-18]3'-f-pib and [c-11]pib in alzheimer's disease and control subjects. J. Nucl. Med. 2007, 48 (Suppl. 2), 56.
49. Agdeppa, E.D.; Kepe, V.; Liu, J.; Small, G.W.; Huang, S.C.; Petric, A.; Satyamurthy, N.; Barrio, J.R. 2-dialkylamino-6-acylmalononitrile substituted naphthalenes (ddnp analogs): Novel diagnostic and therapeutic tools in alzheimer's disease. Mol. Imaging Biol. 2003, 5(6), 404-417.
50. Kepe, V.; Huang, S.C.; Small, G.W.; Satyamurthy, N.; Barrio, J.R. Visualizing pathology deposits in the living brain of patients with alzheimer's disease. Methods Enzymol. 2006, 412, 144-160.
51. Agdeppa, E.D.; Kepe, V.; Liu, J.; Flores-Torres, S.; Satyamurthy, N.; Petric, A.; Cole, G.M.; Small, G.W.; Huang, S.C.; Barrio, J.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in alzheimer's disease. J. Neurosci. 2001, 21(24), RC189.
52. Ryu, E.K.; Chen, X. Development of alzheimer's disease imaging agents for clinical studies. Front Biosci. 2008, 13, 777-789.
53. Tolboom, N.; Yaqub, M.; van der Flier, W.M.; Boellaard, R.; Luurtsema, G.; Windhorst, A.D.; Barkhof, F.; Scheltens, P.; Lammertsma, A.A.; van Berckel, B.N. Detection of alzheimer pathology in vivo using both 11c-pib and 18f-fddnp pet. J. Nucl. Med. 2009, 50(2), 191-197.
54. Shin, J.; Lee, S.Y.; Kim, S.H.; Kim, Y.B.; Cho, S.J. Multitracer pet imaging of amyloid plaques and neurofibrillary tangles in alzheimer's disease. Neuroimage. 2008, 43(2), 236-244.
55. Mullani, N.A.; Gould, K.L. First-pass measurements of regional blood flow with external detectors. J. Nucl. Med. 1983, 24(7), 577-581.
56. Mullani, N.A.; Goldstein, R.A.; Gould, K.L.; Marani, S.K.; Fisher, D.J.; O'Brien, H.A. Jr.; Loberg, M.D. Myocardial perfusion with rubidium-82. I. Measurement of extraction fraction and flow with external detectors. J. Nucl. Med. 1983, 24(10), 898-906.
57. Nandalur, K.R.; Dwamena, B.A.; Choudhri, A.F.; Nandalur, S.R.; Reddy, P.; Carlos, R.C. Diagnostic performance of positron emission tomography in the detection of coronary artery disease: a meta-analysis. Acad. Radiol. 2008, 15(4), 444-451.
58. Di Carli, M.F., Dorbala, S. Cardiac pet-ct. J. Thorac. Imaging. 2007, 22(1), 101-106.
59. Bateman, T.M.; Heller, G.V.; McGhie, A.I.; Friedman, J.D.; Case, J.A.; Bryngelson, J.R.; Hertenstein, G.K.; Moutray, K.L.; Reid, K.; Cullom, S.J. Diagnostic accuracy of rest/stress ecg-gated rb-82 myocardial perfusion pet: Comparison with ecg-gated tc-99m sestamibi spect. J. Nucl. Cardiol. 2006, 13(1), 24-33.
60. Santana, C.A.; Folks, R.D.; Garcia, E.V.; Verdes, L.; Sanyal, R.; Hainer, J.; Di Carli, M.F.; Esteves, F.P. Quantitative (82)rb pet/ct: Development and validation of myocardial perfusion database. J. Nucl. Med. 2007, 48(7), 1122-1128.
61. Yano, Y.; Anger, H.O. Visualization of heart and kidneys in animals with ultrashort-lived 82rb and the positron scintillation camera. J. Nucl. Med. 1968, 9(7), 413-415.
62. Chander, A.; Brenner, M.; Lautamaki, R.; Voicu, C.; Merrill, J.; Bengel, F.M. Comparison of measures of left ventricular function from electrocardiographically gated 82rb pet with contrastenhanced ct ventriculography: A hybrid pet/ct analysis. J. Nucl. Med. 2008, 49(10), 1643-1650.
63. nded. Lippincott, Williams and Wilkins: Philadelphia, 2009.
64. Schelbert, H.R.; Phelps, M.E.; Huang, S.C.; MacDonald, N.S.; Hansen, H.; Selin, C.; Kuhl, D.E. N-13 ammonia as an indicator of myocardial blood flow. Circulation. 1981, 63(6), 1259-1272.
65. Krivokapich, J.; Huang, S.C.; Phelps, M.E.; MacDonald, N.S.; Shine, K.I. Dependence of 13nh3 myocardial extraction and clearance on flow and metabolism. Am. J. Physiol. 1982, 242(4), H536-542.
66. Thomlinson, R.H., Gray, L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer. 1955, 9(4), 539-549.
67. Nordsmark, M.; Overgaard, M., Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 1996, 41(1), 31-39.
68. Brizel, D.M.; Sibley, G.S.; Prosnitz, L.R.; Scher, R.L., Dewhirst, M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1997, 38(2), 285-289.
69. Lancini, G.C., Lazzari, E. The synthesis of azomycin (2-nitroimidazole). Experientia. 1965, 21. 83.
70. Grunbaum, Z.; Freauff, S.J.; Krohn, K.A.; Wilbur, D.S.; Magee, S.; Rasey, J.S. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J. Nucl. Med. 1987, 28(1), 68-75.
71. Rasey, J.S.; Nelson, N.J.; Chin, L.; Evans, M.L.; Grunbaum, Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat. Res. 1990, 122(3), 301-308.
72. Rasey, J.S.; Koh, W.J.; Evans, M.L.; Peterson, L.M.; Lewellen, T.K.; Graham, M.M.; Krohn, K.A. Quantifying regional hypoxia in human tumors with positron emission tomography of 18f fluoromisonidazole: A pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36(2), 417-428.
73. Swanson, K.R.; Chakraborty, G.; Wang, C.H.; Rockne, R.; Harpold, H.L.; Muzi, M.; Adamsen, T.C.; Krohn, K.A.; Spence, A.M. Complementary but distinct roles for mri and 18ffluoromisonidazole pet in the assessment of human glioblastomas. J. Nucl. Med. 2009, 50(1), 36-44.
74. Read, S.J.; Hirano, T.; Abbott, D.F.; Sachinidis, J.I.; Tochon-Danguy, H.J.; Chan, J.G.; Egan, G.F.; Scott, A.M.; Bladin, C.F.; McKay, W.J.; Donnan, G.A. Identifying hypoxic tissue after acute ischemic stroke using pet and 18f-fluoromisonidazole. Neurology. 1998, 51(6), 1617-1621.
75. Rajendran, J.G.; Schwartz, D.L.; O'Sullivan, J.; Peterson, L.M.; Ng, P.; Scharnhorst, J.; Grierson, J.R.; Krohn, K.A. Tumor hypoxia imaging with [f-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin. Cancer Res. 2006, 12(18), 5435-5441.
76. Lee, N.; Nehmeh, S.; Schoder, H.; Fury, M.; Chan, K.; Ling, C.C.; Humm, J. Prospective trial incorporating pre-/mid-treatment [18f]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75(1), 101-108.